The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Clover Health Investments Corp. (CLOV) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.0154, or 1.68%, to $0.93. The Clover Health Investments Corp. has recorded 145,351 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that Clover Health to Present at Barclays 2023 Global Healthcare Conference on March 14, 2023.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
The company is listed on the NASDAQ and operates within the Healthcare Plans industry segment. At the end of the last regular session, the stock closed at $0.91 and fluctuated between $0.9550 as its day high and $0.9000 as its day low. The current market capitalization of Clover Health Investments Corp. is $458.30M. A total of 7.77 million shares were traded on the day, compared to an average of 7.03M shares.
Furthermore, investors take into consideration insider trades when predicting a stock’s future trajectory. During the recent three months, CLOV has seen 8 BUY and 0 SELL insider trades, representing the acquisition of 11,150,441 and the disposition of 0 shares. Over the last 12 months, there were 27 BUYs and 0 SELLs from insiders. Insiders purchased 25,755,680 shares during that period but sold 0.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. According to analysts who have offered 12-month price targets for CLOV in the last 3 months, the mean price target is $1.66 with high estimates of $3.00 and low estimates of $1.15. In terms of 52-week highs and lows, CLOV has a high of $3.90 and a low of $0.86.
As of this writing, CLOV has an earnings estimate of -$0.25 per share for the current quarter. EPS was calculated based on a consensus of 5 estimates, with a high estimate of -$0.16 per share and a lower estimate of -$0.36. The company reported an EPS of -$0.22 in the last quarter, which was -4.80% lower than expectations of -$0.21.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information.
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 6 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CLOV is Overweight with a score of 3.25. A total of 1 analysts rated the stock as Buy while 0 rated it as Overweight while 3 rated it as Hold. Among the other participants, 1 thought the stock was Underweight and 1 thought it should be Sold.